Growth Metrics

Northwest Biotherapeutics (NWBO) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$1.5 billion.

  • Northwest Biotherapeutics' Retained Earnings fell 634.31% to -$1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 billion, marking a year-over-year decrease of 634.31%. This contributed to the annual value of -$1.4 billion for FY2024, which is 616.14% down from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Retained Earnings of -$1.5 billion as of Q3 2025, which was down 634.31% from -$1.5 billion recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Retained Earnings registered a high of -$1.2 billion during Q4 2021, and its lowest value of -$1.5 billion during Q3 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$1.4 billion (2023), whereas its average is -$1.4 billion.
  • Examining YoY changes over the last 5 years, Northwest Biotherapeutics' Retained Earnings showed a top increase of 1306.33% in 2021 and a maximum decrease of 6428.22% in 2021.
  • Over the past 5 years, Northwest Biotherapeutics' Retained Earnings (Quarter) stood at -$1.2 billion in 2021, then decreased by 8.81% to -$1.3 billion in 2022, then fell by 4.83% to -$1.4 billion in 2023, then dropped by 6.16% to -$1.4 billion in 2024, then fell by 4.26% to -$1.5 billion in 2025.
  • Its Retained Earnings stands at -$1.5 billion for Q3 2025, versus -$1.5 billion for Q2 2025 and -$1.5 billion for Q1 2025.